The US Food and Drug Administration (FDA) on Tuesday, October 27, 2026, published draft guidance that would streamline approvals of some individualized gene therapies, according to STAT1. These are gene treatments built for very small groups of patients, sometimes a single person, who carry rare genetic mutations1. STAT described the document as offering new details on a quicker approval pathway for these personalized treatments1.
Rare disease advocates, who have criticized the agency’s approach to these treatments, called the draft a win1. It is not a final rule, and it does not approve any treatment.
What happened
A guidance document is the FDA’s way of telling drug developers how it plans to review a type of product and what it expects to see. This one focuses on gene therapies tailored to individual patients1. Gene therapies are treatments that aim to treat or cure diseases by altering faulty genes inside a person’s cells1.
STAT reported that the draft would make approval of some of these therapies more streamlined1. The word “some” matters: the draft does not cover every custom gene therapy, and which ones qualify is spelled out in the guidance itself.
Paul Scribner, vice president of community programs and education at the PKD Foundation, a patient organization, spoke about the draft at a rare disease event on the same day1:
“It’s sort of putting a flag in the ground and saying, ‘This is important,’”
That quote comes from STAT’s report1.
Why custom gene therapies are a hard fit for the usual rules
Advances in gene therapy have energized researchers and companies who believe many patients with rare mutations could benefit from personalized medicines1. The difficulty is that the normal drug approval system was built around testing a treatment in large groups of people. When a disease is caused by a mutation found in only a handful of patients, or one, large trials are not possible.
The FDA has acknowledged parts of this problem for years. In 2018, it described a draft guidance for gene therapies in rare diseases as aiming to help developers whose programs face small study populations, feasibility and safety issues, and questions about how to judge whether a treatment worked2. Individualized therapies push those same problems to the extreme.
There is also the question of how long a benefit lasts. In 2020, the FDA said that reviewing gene therapies often raises harder questions than reviewing more conventional drugs, including how durable the response is3. The agency said then that, for some gene therapy products that meet its approval standards, it may need to accept some uncertainty about how long the response lasts at the time of approval3.
What this does not show yet
The reporting available to Biohack describes the draft’s purpose and the reaction to it, but not the full list of what developers would need to show to use the quicker path1. Readers should be cautious about summaries that claim to know exactly which therapies qualify until the document’s details are widely reported or reviewed.
Several things remain open:
- It is a draft. When the FDA released a set of gene therapy guidance in 2018, then-Commissioner Scott Gottlieb said the documents were issued in draft form to collect public input, and that comments would be carefully considered before they were finalized2. The new document could change in the same way before it becomes final.
- No therapy has been approved under it. Guidance sets out the agency’s thinking. It does not decide whether any single treatment is safe or effective.
- Faster review does not remove long-term questions. In past gene therapy guidance, the FDA stressed long-term follow-up of patients to watch for safety problems that appear over time3. A 2018 summary of the agency’s approach noted that tools for reliable follow-up after approval, such as required post-market trials, are important when questions about durability remain unanswered at approval2.
Who is pushing for it
The draft comes from the FDA itself. The loudest early support comes from rare disease advocates, who have criticized how the agency has handled these treatments1. STAT’s subheadline said advocates applauded the effort to ease access to custom treatments1.
Researchers and companies working on gene therapies for rare mutations also have a stake, since a clearer and quicker route could make it more practical to develop treatments for very small patient groups1. The sources reviewed for this article do not name specific companies that plan to use the new pathway or describe any industry funding behind the push.
How it fits with the FDA’s earlier gene therapy rules
This draft is the latest in a series of FDA efforts to set rules for gene therapy as the field has grown.
- 2018: Gottlieb announced six scientific guidance documents meant to give the field a fuller framework2. Three were new drafts covering gene therapy for hemophilia, retinal disorders and rare diseases2. Three updated older documents from 2006 and 2008 on manufacturing, testing for a specific safety risk with certain virus-based products, and long-term follow-up2.
- 2020: The FDA finalized a slate of gene therapy policies, saying it was preparing for a surge of new treatments in diseases like hemophilia and muscular dystrophy3. At the time, it expected to be reviewing and approving between 10 and 20 cell and gene therapies each year by 20253. BioPharma Dive reported that nearly 1,000 gene therapy studies were underway then3.
Those earlier documents mostly dealt with products meant for a defined disease population, such as all patients with a certain form of hemophilia. The new draft focuses on individualized therapies, made for people whose mutations are so rare that a treatment may be designed for them specifically1.
The 2020 FDA statement captures the tension the new draft tries to manage. Then-Commissioner Stephen Hahn said: “These therapies, once only conceptual, are rapidly becoming a therapeutic reality”3. At the same time, the agency said it may have to accept some uncertainty about how long benefits last when it approves them3.
What to watch next
- The details. Which therapies qualify for the quicker path, and what evidence developers must provide, will shape how much the draft changes in practice.
- Public comments. Based on how the FDA has handled past drafts, patient groups, researchers and companies are likely to weigh in before a final version2.
- Safety follow-up. Whether the final guidance keeps strong long-term monitoring requirements, which the FDA has repeatedly called a priority for gene therapies3.
- First users. Whether any developer announces plans to seek approval of a custom gene therapy using this route, and how the FDA rules on it.
For now, the news is that the FDA has put on paper a plan to make approval of some one-patient and few-patient gene therapies faster, and that rare disease advocates see it as a meaningful signal1. How much it speeds things up, and for whom, will depend on details that are still to be tested and could still change.
